Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/185580
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
OBJECTIVES This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials.BACKGROUND The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF).METHODS Adults with symptomatic HF and LVEF > 40%, with or without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo.RESULTS A total of 6,263 patients were randomized (mean age: 72 & PLUSMN; 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index $30 kg/m(2); and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 & PLUSMN; 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF. CONCLUSIONS DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, welltreated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).
Subject
Subject (English)
Citation
Citation
SOLOMON, Scott D., et al. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure. 2022. Vol. 10, num. 3, pags. 184-197. [consulted: 21 of May of 2026]. Available at: https://hdl.handle.net/2445/185580